Repaglinide for treatment of newly diagnosed type 2 diabetes mellifus

Objective: To observe the efficacy of repaglinide in treatment of newly diagnosed type 2 diabetes mellitus. Methods: Two hundred patients who were newly diagnosed to have type 2 diabetes mellifus were administered repaglinide 1.0 mg 3 times a day before meals in addition to the therapy of diet-control and adequate exercise. And the effect was observed in the following 16 weeks. The BMI,blood fat,fasting blood glucose,blood glucose 2 hours after meals,HbA1C and fasting insulin at 8 weeks and 16 weeks after the therapy were detected. Results: After 16 weeks of treatment,the fasting blood glucose,blood glucose 2 hours after meals and HbA1C were significantly decreased (P < 0.01). Conclusions: Repaglinide may effectively control the blood glucose of patients with type 2 diabetes with few adverse reactions and a low incidence of hypoglycemia.